Alterity Therapeutics Limited
ATHENASDAQ
Healthcare
$3.56
-0.08(-2.22%)
Mkt Cap $32M
$2.54
$6.55
52-Week Range
At a Glance
AI-generated6-K
Alterity Therapeutics received positive FDA feedback on clinical pharmacology and non-clinical elements for its ATH434 Phase 3 program in Multiple System Atrophy following a Type C Meeting.$32M
Market Cap
$9.9K
Revenue
-$37.8K
Net Income
Employees10
Fundamentals
How The Business Makes Money
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001131343
ISINUS02155X2053
CUSIP02155X106
Phone61 3 9349 4906
Address460 Bourke Street, Melbourne, VIC, 3000, AU
SEC EDGAR